Can a rapid drug switch outsmart advanced kidney cancer?
NCT ID NCT05188118
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This pilot study is testing whether a rapid, timed sequence of different drugs can improve outcomes for people with advanced or inoperable clear cell kidney cancer. Participants first receive cabozantinib, then a combination of two immunotherapies (ipilimumab and nivolumab), followed by further treatment based on how their cancer responds. The goal is to see if this fast-switching strategy can shrink tumors or slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a rapid sequence of cabozantinib, ipilimumab, nivolumab, lenvatinib, and everolimus
- What this could lead to
- If successful, this approach could point toward a more effective treatment strategy for advanced kidney cancer by rapidly switching between drug classes.
- What could go wrong
- This is a very early, small pilot study with only 10 participants, so results may not apply broadly. The combination of multiple drugs also raises the risk of significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?